Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHESGO neoadjuvant-to-adjuvant therapy in Nigerian women with HER2-positive breast cancer
PACTR202406683851265Phase 2Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by University of Chicago. Primary endpoint: Pathological complete response in the breast at surgery. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202406683851265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202406683851265.